Analysis of dietary vitamin C intake levels and the risk of

hyperuricemia and gout based on cross-sectional studies and bi-

directional Mendelian randomisation

- Zi-Ning Peng^{1†}, Xing-Qiang Wang^{2,3†}, Qian Deng¹, Wei-Tian Yan¹, Wei-Qing Zhao⁴, Yong-Bin Pu², 1
- Nian Liu^{1,3*}, Ling-Li Gu^{2*}, Jiang-Yun Peng^{2,3*} 2
- ¹First school of clinical medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, 3
- 650500, PR China 4
- 5 ²Department of Rheumatology, The No.1 Affiliated Hospital of Yunnan University of Chinese
- Medicine, Kunming, Yunnan, 650021, PR China 6
- ³Yunnan Provincial Clinical Medicine Research Center of rheumatism in TCM, Yunnan provincial 7
- hospital of traditional Chinese medicine, Yunnan, 650021, PR China 8
- ⁴Department of Rheumatology and Immunology, The First People's Hospital of Yunnan Province 9
- and The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 10
- 650034, PR China 11
- 12

† Co-first Author 13

- 14
- Zi-Ning Peng E-mail: pzn2019@126.com 15
- Xing-Qiang Wang 16
- E-mail: ouyangfengyangguo@163.com 17
- * Correspondence: 18
- Nian Liu 19
- E-mail: liunian8917@163.com 20
- 21 Jiang-Yun Peng
- E-mail: pengjiangyun@126.com 22
- Ling-Li Gu 23
- E-mail: guyuxin82@126.com 24
- Preferred language: British English 25
- 26 Number of words: 3,929
- Number of figures and tables: 4 figures and 7 tables 27
- **Running title:** Vitamin C and hyperuricemia/gout risk 28
- Keywords: vitamin C, NHANES, Mendelian randomisation, hyperuricemia, gout, cross-sectional 29 study 30
- Abstract 31
- Background: Vitamin C, a common antioxidant, may be useful for treating hyperuricemia and gout. 32
- The aim of this study was to investigate the risk association between dietary vitamin C intake and 33
- hyperuricemia/gout and to test for causality using the bi-directional Mendelian randomisation 34
- method. 35

Methods: Cross-sectional studies were selected from the National Health and Nutrition 36 Examination Survey from 2007–2018 to assess the association between dietary vitamin C intake 37 38 and the risk of hyperuricemia/gout, according to multivariate logistic regression modelling. Bidirectional Mendelian randomisation studies were conducted using genetic data from large-scale 39 genome-wide association surveys of supplemental vitamin C, pharmacological vitamin C, and 40 ascorbic acid intake and hyperuricemia/gout; these aimed to infer causal relationships between 41 vitamin C and hyperuricemia/gout. Inverse variance weighting was used as the primary method of 42 Mendelian randomisation analysis. A series of sensitivity analyses were used to assess multiplicity. 43 44 Results: The cross-sectional study included 17.52% and 82.48% patients with and without hyperuricemia, respectively, as well as 2.67% and 97.33% patients with and without gout, 45 respectively. In the model correcting for all covariates, the association between vitamin C intake 46 and the risk of hyperuricemia/gout was stable, and the risk of hyperuricemia was generally lower 47 in patients who consumed >111.75 mg vitamin C than in other patients when comparing three 48 models with different moderators. Restricted cubic spline scores indicated that vitamin C intake 49 recommendations of 75–525 mg and 75–225 mg were effective for targeting hyperuricemia and 50 gout, respectively. In inverse variance weighting in the Mendelian randomisation analysis, the 51 amount of vitamin C absorbed was negatively associated with hyperuricemia (OR = 0.985, 95% CI 52 = 0.973 - 0.997, p = 0.015), and supplemental vitamin C was negatively associated with gout (OR = 53 0.857, 95% CI = 0.797-0.921, p < 0.001; sensitivity analysis yielded consistent results. Reverse 54 55 Mendelian randomisation analysis showed that vitamin C had no reverse causal relationship with hyperuricemia and gout. 56

57 **Conclusion:** We hypothesise that a dietary vitamin C intake of 75–525 mg or 75–225 mg may 58 reduce the risk of hyperuricemia and gout, respectively. Further research with larger samples is 59 required to confirm this.

60 **1** Introduction

Gout has long been known as the "disease of kings" because of the disproportion rates of gout in royal families (1). In modern society, hyperuricemia (HUA) and other musculoskeletal diseases are common medical issues due to improvements in living standards (2). Cases of HUA and gout are increasing globally, particularly in higher-income, developed economies. Although current epidemiological data are incomplete, approximately one in five people are affected by increased uric acid levels and their effects; the prevalence of HUA and gout are approximately 20% and 2.6%, respectively (3, 4).

Generally, gout begins as asymptomatic HUA, gradually developing into clinical symptoms 68 accompanied by uric acid crystal deposits in the joint cavities, and finally advancing to a diagnosis 69 of gout. This continuous process produces a series of complications (5). Persistent HUA can easily 70 trigger end-stage diseases, resulting in increased mortality. Therefore, controlling high uric acid 71 levels is crucial in determining treatment opportunities for gout. Epidemiological research shows 72 that behavioural factors, especially dietary factors, affect uric acid metabolism. Although several 73 anti-gout medications, such as febuxostat and colchicine, have been approved for use by the US 74 Food and Drug Administration in recent years, these medications have significant adverse effects, 75 including renal and hepatic failure and cardiotoxicity (6). Therefore, vitamin C (VC) has piqued the 76 interest of researchers as a common antioxidant. 77

VC, also known as ascorbic acid, plays a pleiotropic role in living organisms. In 1932, Hungarian

- biologist Albert Szent-Györgyi first discovered VC and used it to regulate different biological processes (7). VC possesses bi-directional properties, acting as both an antioxidant and a prooxidant. Additionally, it exhibits properties that are related to the immune system. These characteristics of VC can aid in reducing HUA (8). Although dietary approaches appear to play an important role in preventing gout attacks or the onset of the disease, a comprehensive understanding of the interaction between uric acid and VC in the human body remains insufficient.
- 85 In HUA- or gout-related research, it is already very common to observe the protective properties of
- 86 VC. For example, research shows that dietary and supplemental VC intake are negatively correlated
- 87 with HUA risk (9). However, focusing solely on HUA is insufficient; therefore, our research also
- 88 included participants with gout. In addition, the National Health and Nutrition Examination Survey
- 89 (NHANES) 2007-2018 was used to add more data compared to previous research, and quartiles of
- 90 dietary VC were observed. Supplemental VC was not considered as part of the overall dietary intake
- 91 to avoid potential disruptions in our analysis; therefore, the effects of supplemental VC were
- 92 excluded from our study.
- 93 Mendelian randomisation (MR) is an epidemiological method that uses genetic variation as an
- 94 instrumental variable (IV) to represent exposure to a variable of interest. It is also used to investigate
- 95 the effect of exposure on specific outcomes (10). In the present study, we investigate the underlying
- 96 causal relationship between VC and gout/HUA. We performed MR analysis using genome-wide
- 97 association study (GWAS) data. MR is the ideal tool for studying immune diseases because when
- 98 exposed to external environmental factors, genetic variables can affect life expectancy. We used the
- 99 bi-directional MR method to analyse and predict the causal effects of VC on gout and HUA, which 100 helped mitigate bias from dietary questionnaires in the NHANES database, thereby enhancing the
- 101 reliability of the results.

102 2 Material and Methods

103 This study consisted of two parts. In the first part, we conducted a study using data from a large 104 sample of the NHANES to explore the association between VC intake and HUA/gout. Due to 105 questionnaire bias in the NHANES database, we supplemented the second part with a bi-directional 106 MR analysis utilising GWAS pooled statistics to reduce bias and avoid reverse causality and 107 assessed the causal effects of VC intake on HUA and gout. The overall study design is shown in 108 Figure 1.

109 2.1 Cross-sectional Study

110 2.1.1 Study Population

NHANES examined a nationally representative sample of the civilian non-institutionalised 111 population of the USA of all ages using a complex multistage probability design. We used the most 112 recent NHANES database containing data from six cycles (2007–2018) (n = 59,842). Figure 1A 113 shows the NHANES 2007-2018 sample selection flowchart. Following a home interview, 114 participants were invited to complete additional questionnaires, undergo testing, and provide blood 115 and other biospecimens in a mobile examination centre. The National Centre for Health Statistics 116 Research Ethics Review Board approved NHANES, and all participants provided informed consent 117 for the home interview and tests at the mobile examination centre. There were 28,227 participants 118 aged 18 years or older who were eligible for the dietary questionnaire in this survey. Individuals 119

- 120 who did not provide a blood uric acid specimen (n = 1,455), those who currently or previously had
- 121 a tumour (self-reported) (n = 3,801), and those taking uric acid-lowering medications (allopurinol,
- febuxostat, or probenecid) that interfered with the investigation (n = 291) were excluded, and the
- remaining 22,680 individuals were enrolled in our next step of analysis.

124 2.1.2 Dietary VC Intake

- 125 Dietary VC intake was assessed using 24 h recall. Relying on the US Department of Agriculture
- 126 Food and Nutritional Database (2007–2018) to determine the nutrient composition, supplied energy,
- 127 and other components of diet and fluids, all participants underwent two 24 h recalls. The interviews
- 128 included all types of food and fluids consumed. Thereafter, we analysed the average VC intake,
- 129 including VC from all meals consumed by the participants, while excluding VC from supplements.

130 2.1.3 HUA and Gout Diagnosis

- 131 Serum concentrations of uric acid were measured using the Beckman UniCel® DxC 800 Synchron
- 132 or Beckman Synchron LX20 (Beckman Coulter, Inc., Brea, CA, United States) after the uric acid
- 133 was oxidised by uricase to form allantoin and H₂O₂. HUA was diagnosed when uric acid levels
- 134 were \geq 420 µmol/l (7 mg/ dL) in men and \geq 360 µmol/l (6 mg/dL) in women (11). Gout flares were
- 135 defined by self-assessment in a questionnaire.

136 **2.1.4 Covariates**

- 137 Demographic characteristics included age, sex, race (Hispanic American, non-Hispanic white, non-
- 138 Hispanic black, and other races), marital status (married, widowed, divorced, and unmarried), and
- education level (less than high school, high school graduate, and equal to college and above). Other
- 140 covariates included smoking status (never, ex-smoker, and current persistent smoker), alcohol use
- 141 (defined as at least one drink per month in the last year), poverty level, body mass index, and waist
- 142 circumference. History of cardiovascular disease, hypertension, hyperlipidaemia, kidney stones,
- 143 and diabetes mellitus were defined as self-reported medical diagnoses. Glomerular filtration rate
- 144 was used to assess renal function, which was calculated using the CKD-EPI creatinine equation
- 145 (12). Blood specimens were processed, stored, and shipped to their respective laboratories for 146 analysis, including creatinine, glucose, cholesterol, triglyceride, direct cholesterol, and uric acid
- 147 analysis.

148 2.1.5 Statistical Analysis

R version 4.2.2 was used for all analyses. Counts and proportions were used for categorical 149 variables, whereas means and standard deviations were used for continuous data, and sampling 150 weights were considered for all analyses. For two-tailed tests, p < 0.05 was considered statistically 151 significant. Based on VC intake quartiles, subjects were categorised into Q1 (0-29.1 mg), Q2 (29.1-152 61.0 mg), Q3 (61.0-111.75 mg), and Q4 (>111.75 mg), and descriptive statistics were used to 153 analyse the characteristics of the participants. Categorical variables were compared using the Chi-154 square test, and continuous variables were compared using ANOVAs or the Kruskal-Wallis H test. 155 In this study, three models were produced: Model 1 included all variables, Model 2 corrected for 156 some demographically relevant variables, and Model 3 corrected for all covariates. Logistic 157 regression models and restricted cubic spline analyses were carried out to assess the correlation 158

159 between dietary VC intake with the risk of developing gout and HUA.

160 2.2 Bi-directional MR Study

161 **2.2.1 Study Design**

- 162 The overall design of the MR study is shown in Figure 1B. To obtain valid causal effect estimates,
- 163 IVs in the forward MR model need to meet the following three conditional assumptions: 1) genetic
- variations are significantly associated with VC intake levels; 2) genetic variations are not associated
- 165 with other confounders; and 3) they affect gout or HUA only through the VC intake levels. Inverse
- 166 MR model IVs need to meet the following three conditional assumptions: 1) genetic variations are
- significantly associated with gout or HUA; 2) genetic variations are not associated with other
- 168 confounders; and 3) they affect VC intake levels only through gout or HUA.

169 **2.2.2 Data Sources and Genetic Tools**

- 170 Genetic tools were mainly derived from the latest GWAS meta-analysis, i.e. GWAS summary data
- 171 (13). GWAS is a genome-wide test of polymorphic genetic variants (markers) in multiple
- 172 individuals, enabling researchers to obtain genotypes for statistical analysis at the population level.
- 173 We used GWAS to identify sequence variants, known as single nucleotide polymorphisms (SNPs),
- 174 present on a genome-wide scale in humans. From this, we screened for SNPs associated with HUA,
- gout, and VC intake (14). HUA and gout data were obtained from the EBI database in the GWAS
- 176 database, and VC data were obtained from the UKB database. Due to the lack of GWAS data on
- 177 dietary VC, for the sake of completeness, we used all VC-related data from the UKB database for
- 178 MR analysis, including data on "supplements: vitamin C", "medication: vitamin C" and "vitamin
- 179 C absorbated". The specific data examined in this study are shown in Supplementary Table 1.

180 2.2.3 Statistical Analysis

MR analysis was mainly performed using inverse variance weighting (IVW)-random effects and 181 IVW-fixed effects models. All statistical analyses were performed using "two sample MR" in R 182 software. In addition, weighted median and MR-Egger regression were applied to supplement the 183 analyses. Heterogeneity and pleiotropy among the selected SNPs were assessed using Cochrane Q-184 analysis and MR-Egger intercepts. Leave-one-out analysis was performed to test whether the 185 estimates were driven by individual SNPs. Statistical power and F-statistic computational 186 measurements ensured sufficient statistical efficacy to avoid weak IV bias. Power calculation was 187 performed using the online tool mRnd¹ and the IV was deleted when the IV strength measure F-188 statistic was <10 to minimise the chance of MR analysis bias. Finally, reverse MR was applied to 189 test for the presence of reverse causal links. 190

191 **3 Results**

192 **3.1 Cross-sectional Study**

193 **3.1.1 Basic Characteristics of Study Participants**

194 Tables 1 and 2 summarise the overall characteristics of the study participants, that is, whether they

had HUA and gout, respectively. Among the participants, 17.52% had HUA and 82.48% did not

- have HUA, whereas 2.67% had gout and 97.33% did not have gout. Separate analyses were
- 197 performed according to sex, race, marital status, education, alcohol consumption, smoking status,
- 198 hypertension, hyperlipidaemia, and diabetes, in relation to the presence of HUA or gout. Table 1

- shows that, with the exception of alcohol consumption (p = 0.8) and poverty level (p = 0.2), all other variables exhibit statistically significant differences (p < 0.001) between individuals with HUA and those with kidney stones (p = 0.006). Table 2 shows that, in addition to education level (p = 0.4), poverty level (p = 0.4), and cholesterol (p = 0.6), race (p = 0.014), alcohol consumption (p = 0.006), and VC (p = 0.003) showed statistical significance with regard to having gout. Furthermore, the other covariates showed statistically significant differences with regard to having gout (p < 0.001). The overall basic characteristics indicated that the prevalence of HUA and gout
- was higher in men than in women, and that patients with HUA and gout had lower VC intake than
- 207 patients without these diseases.

208 3.1.2 Relationship Between HUA/Gout and VC Intake Level

- Table 3 demonstrates the relationship between HUA/gout and VC intake level quartile. Logistic
- regression showed that Model 1, which did not correct for any variables, had the weakest correlation
 between VC intake level and the risk of HUA/gout. Model 2 increased the association between VC
- intake and the risk of HUA/gout; it controlled for age, sex, race, marital status, education, alcohol
- consumption, and smoking-related demographic variables. Model 3 corrected all covariates. After
- correction, the correlation between VC intake and the risk of HUA and gout in Model 3 was stable.
- Additionally, in these three models, VC intake and the risk of HUA in Q4 were generally lower
- than in Q1–3. After correcting for covariates, the protective effects of VC became increasingly
- evident from Model 1 to Model 3.

218 **3.1.3 Dose–response Relationship Between HUA/Gout and VC Intake**

- 219 After completely adjusting for confounding factors and correcting for all covariates, restricted cubic
- 220 spline analysis was performed for HUA/gout and VC intake, respectively. This showed that VC
- intake had a non-linear relationship with both HUA (p < 0.0001) and gout (p = 0.001) in participants
- affected by either (Figure 2). Among these participants, a VC intake of 75–525 mg and 75–225 mg
- 223 can effectively target HUA and gout, respectively.

224 3.2 Bi-directional MR Study

225 3.2.1 MR Analysis Using IVs Based on GWAS

- SNPs were selected according to the following criteria: SNPs related to confounding factors 226 between VC and HUA were excluded (e.g. those related to haemolysis, diabetes, cholesterol, 227 lymphoma, chemotherapy, alcohol, metabolic syndromes, metabolism, and gout); SNPs related to 228 confounding factors between VC and gout were excluded (e.g. those related to diabetes, cholesterol, 229 alcohol, metabolic syndromes, metabolism, uric acid levels, HUA, and hypertension); SNPs related 230 to the results; and SNPs that were not present in the results. For MR analysis, we selected all SNPs 231 with critical values of $p < 1 \times 10^{-5}$ related to HUA/gout–VC absorbates; the remaining selection (p 232 $< 1 \times 10^{-6}$) was used as an IV to increase the number of available SNPs and to facilitate subsequent 233 sensitivity analyses. 234
- 235 We assessed the causal relationship between VC and HUA/gout based on different IVs (Table 4).
- 236 The MR results show a causal relationship between VC absorbates and HUA; the MR IVW results
- show a negative correlation between VC absorbates and HUA (OR = 0.985, 95% CI = 0.973–0.997,
- p = 0.015). The results of all three other methods, MR-Egger, weighted median, and weighted mode,
- 239 were statistically significant (p < 0.05), consistent with the IVW results. Figure 3A shows a

- 240 scatterplot of the correlation between SNPs and HUA, as well as between SNPs and VC absorbates.
- 241 Figure 3B shows a forest plot for each SNP in VC absorbate-HUA estimation, suggesting the
- 242 magnitude of the MR effects of VC on HUA. As shown in Table 4, no statistically significant
- relationship was observed between supplemental VC or pharmacological VC and HUA in this MR
- 244 analysis.
- In addition, the MR IVW analysis results show a causal relationship between supplemental VC and
- 246 gout (OR = 0.857, 95% CI = 0.797-0.921, p < 0.001), supported by the weighted median method
- (p < 0.05); correlation scatter plots and forest plots indicate the magnitude of the MR effect of VC on gout, as shown in Figure 4A and B. However, there was no statistically significant relationship
- between supplemental VC absorbates or pharmacological VC and gout in the MR analysis, as
- shown in Table 4.

251 3.2.2 MR Sensitivity Analysis

- 252 We estimated the stability of the MR results using sensitivity analysis, as shown in Table 5. In the
- 253 analysis of VC absorbates versus HUA, Cochran's Q test showed that there was slight heterogeneity
- in the MR-Egger analysis (p = 0.049). The MR-Egger intercept test indicated that the MR analyses were not affected by horizontal pleiotropy (p > 0.05). Leave-one-out sensitivity analysis confirmed
- were not affected by horizontal pleiotropy (p > 0.05). Leave-one-out sensitivity analysis confirmed the robustness of the MR results, and the absence of major SNPs (Figure 3C) greatly affected the
- results when eliminated. In addition, for the analysis of supplemental VC versus gout, Cochran's Q
- test showed no heterogeneity in the MR-Egger analysis (p > 0.05), and the results of the MR-Egger
- intercept test indicated that the MR analysis was not affected by horizontal pleiotropy (p > 0.05).
- 260 Leave-one-out sensitivity analysis showed no major SNPs that would greatly affect the results when
- eliminated, confirming the robustness of the MR results, as shown in Figure 4C.

262 **3.2.3 Reverse MR Analysis of the Causal Relationship Between VC and HUA/Gout**

- We performed reverse MR analysis to estimate whether VC would affect HUA/gout using SNPs with critical values of $p < 5 \times 10^{-8}$ as IVs. The reverse MR results are shown in Table 6. The results show that there is no reverse causal relationship between absorbed VC and HUA (p > 0.05 for all five MR methods). Additionally, there was no reverse causal relationship between supplemental VC and gout (p > 0.05 for all five MR methods).
- 268 Four MR methods exhibited no reverse causal relationship between supplemental VC and HUA (p>
- 269 0.05), whereas two methods showed no reverse causal relationship between pharmacological VC
- and HUA (p > 0.05). Each MR method found no reverse causal relationship between any form of
- 271 VC and gout (p > 0.05).

272 3.2.4 Reverse MR Sensitivity Analysis

- Cochran's Q test showed no heterogeneity in the reverse MR analysis of absorbed VC and HUA (p > 0.05), whereas there may be slight heterogeneity in the reverse MR analysis of supplemental VC and gout (p = 0.035). In addition, the MR-Egger intercept test showed that the inverse MR analyses of absorbed VC versus HUA and supplemental VC versus gout were not affected by pleiotropy (p > 0.05) (Table 7). Finally, leave-one-out sensitivity analysis confirmed the robustness
- of the reverse MR results (Supplementary Figures 1 and 2).

279 **4 Discussion**

- 280 There is evidence from prospective epidemiological studies that dietary factors are clinically
- associated risk factors for HUA and gout, including evidence for the protective effects of VC (15).

- 282 Some researchers considered that the urate-lowering effect of VC seemed to be more important
- than other functions. They further explored the potential mechanism of its urate-lowering properties
- and found that VC may reduce urate-induced inflammation by inhibiting the activation of the
- NLRP3 inflammasome (16). Additionally, in vivo studies showed that the VC transporter SVCT1
- acts as a urate importer and that SVCT1 damage can lower serum uric acid levels (17). However,
 studies that confirm the relationship between dietary VC intake, serum uric acid concentration, and
- 288 gout are lacking.
- 289 In this study, we used data from the 2007–2018 NHANES cross-sectional survey and performed
- 290 bi-directional MR analysis to accurately investigate the relationship between gout/HUA risks and
- 291 dietary VC intake levels. The results show that gout/HUA and VC intake are negatively correlated
- in the cross-sectional survey. Restricted cubic spline analysis showed that daily dietary intakes of
- 293 75–525 mg and 75–225 mg VC have protective effects on patients with HUA and gout, respectively.
- In the MR analysis, the causal association between absorbed VC and HUA, as well as supplemental
- 295 VC and gout was consistent with the cross-sectional study.
- Consistent with the present study, the dietary and nutritional factors associated with HUA in the 296 Seventh Korean NHANES showed that dietary fibre intake and VC intake were negatively 297 correlated with HUA (18). Another case-control study on the association between diet/obesity and 298 gout in Taiwan showed that low VC intake increased the risk of gout and that increasing food 299 sources rich in VC and dietary fibre can prevent gout (19). A meta-analysis of randomised 300 controlled trials showed that a median supplementary VC dose of 8 mg/day for at least one week 301 significantly decreased HUA (20). In contrast, current clinical dietary interventions that can reduce 302 the frequency of gout flares (e.g. VC supplementation) can reduce serum uric acid levels and be 303 used as adjuncts for urate-lowering treatment, a non-pharmacological approach to treat gout and 304 HUA (21). 305
- However, further research shows that in patients with gout, continuous VC treatment for eight 306 weeks did not obviously lower uric acid levels, whether this constituted VC alone (500 mg/d) or 307 VC combined with allopurinol. The results of this study may be biased due to a variety of factors 308 such as dose, participants, and course of treatment (22). Overall, neither clinical observational 309 310 studies nor randomised controlled trial meta-analyses can control for confounding factors and bias. Furthermore, most clinical studies are small-scale randomised controlled trials, which cannot 311 control the accuracy of the results. Additionally, interventional studies of dietary VC intake levels 312 and HUA/gout are still lacking, necessitating further research. 313
- MR analysis can appropriately supplement deficiencies when using a large-sample GWAS database 314 without fixed periods and can predict the permanent effects of VC intake. As the current database 315 did not have data related to dietary VC intake, in the present study, it was important to use MR to 316 explore the causal relationship between the risk of HUA/gout and supplemental VC, 317 pharmacological VC, and ascorbic acid, respectively. In the MR results, the genetic susceptibility 318 of absorbed VC with HUA and supplemental VC with gout is not coincidental; forward analysis 319 and reverse MR testing also supported these negative correlations. The potential mechanisms of 320 321 action underlying these effects of VC can include the following.
- First, a gene mutation during the evolution of humans and guinea pigs means that endogenous VC cannot be produced. In addition, VC maintains homeostasis through anti-oxidation and cofactor functions. Blood lacks VC and easily undergoes oxidative stress and peroxide damage, but humans
- and guinea pigs need endogenous supplementation (23, 24). Second, the most important

physiological process in which VC is involved is anti-oxidation. According to research findings, another genetic mutation has been discovered in humans, leading to the elimination of the active uricase gene. This gene can counteract VC deficiency by increasing serum uric acid levels. High intracellular uric acid levels are prone to inducing oxidative stress in the body, and VC reduces the production of mitochondrial Reactive Oxygen Species, increases the level of antioxidant enzymes, and enhances the ability of the body to dissolve uric acid and promote uric acid efflux (25).

However, the VC transporter protein modifies the function and activity of URAT1 in proximal renal 332 tubular cells, thus increasing urate excretion in the body. As the body may obtain more fructose 333 334 than other nutrients during VC intake, the role of VC; however, it will increase the level of uric acid, gout risk, and thus has obvious limitations. A side-by-side study evaluating dietary factors and 335 biochemical indices of patients with gout and asymptomatic HUA confirmed that serum uric acid 336 levels are influenced by dietary factors, and that VC intake in the healthy group was lower than in 337 the disease group. This suggests that dietary intake of energy, protein, and fructose also affects gout 338 and HUA (26). The lack of a significant correlation of supplements: vitamin C and medication: 339 vitamin C with the risk of HUA, and vitamin C absorbated and medication: vitamin C with the risk 340 of gout in the MR study could be attributed to these factors. 341

There are several distinct advantages to the present study. First, not only did this study utilise the 342 NHANES database spanning the longest period, 2007-2018, for data completeness, but it also 343 allowed for an investigation of the association between dietary VC intake and gout/HUA at the 344 epidemiological level. Second, we introduced bi-directional MR analysis, which can address 345 unavoidable influencing factors, such as reverse causality, measurement error, and residual 346 confounders, which exist in ordinary epidemiological studies as well as NHANES data analysis; 347 this adds practical significance to this study. One of the key aspects of this study is its inclusive 348 examination of both gout and HUA, deviating from the conventional approach of focusing solely 349 on a single factor, thus facilitating a more comprehensive investigation of the complexity of this 350 type of immune disease. It facilitated the comparison between each disease to provide more 351 informed advice based on patients in the clinic, as well as experimental direction for researchers to 352 conduct further in vivo and in vitro studies. However, certain limitations exist, including the reliance 353 354 solely on screening and analysis from the intrinsic database and the absence of extensive, prolonged multi-centre clinical research involving a larger sample size. Further research is required to validate 355 the findings through long-term observational and interventional studies. 356

In conclusion, our study supports a causal relationship between dietary VC intake and the risk of 357 HUA, with cross-sectional studies as well as a portion of our MR analyses suggesting a significant 358 negative association. However, despite observational studies suggesting a negative association, 359 other MR analysis did not yield significant results, suggesting that the results might still be 360 influenced by uncontrollable confounding factors. Therefore, based on our findings, we hypothesise 361 that daily dietary VC intake doses of 75–525 mg and 75–225 mg may potentially decrease the risk 362 of HUA and gout, respectively; however, further studies with larger sample sizes are necessary to 363 confirm these findings. 364

365 5 Abbreviations

GWAS, genome-wide association study; HUA, hyperuricemia; IV, instrumental variable; IVW, inverse variance weighting; MR, Mendelian randomisation; NHANES, National Health and Nutrition Examination Survey; SNP, single nucleotide polymorphism; VC, vitamin C

369 6 Conflict of Interest

- 370 The authors declare that the research was conducted in the absence of any commercial or financial
- 371 relationships that could be construed as a potential conflict of interest.

372 **7** Author Contributions

- 373 Z-NP and X-QW conceptualized the study, analyzed and interpreted the data, and revised and edited
- the manuscript. QD, W-TY, W-QZ, Y-BP, NL, J-YP and L-LG drafted the manuscript. NL, J-YP
 QD, W-TY and W-QZ provided advice for the project. NL, J-YP and L-LG provided administrative
- 376 support. All authors read and approved the final manuscript.

377 8 Funding

- 378 This work was supported by the National Natural Science Foundation of China (81960863 and 82160901), Construction Project of Yunnan Provincial Fund for Medical Research Center 379 (202102AA310006), Construction Project of National Traditional Chinese Medicine Clinical 380 381 Research Base (2018 No. 131), Construction Project for the Focal Branch of National Traditional Chinese Medicine (2023 No. 85), The Expert Workstation of Zhangxuan in Yunnan Province 382 (202305AF150175), Funding of Yunnan Applied Basic Research Projects-Union Applied Basic 383 Research Projects-Union Foundation (2019FF002[-082], 2019FF002[-031], 202101AZ070001-384 072 and 202101AZ070001-074), and Yunnan Provincial Traditional Chinese Medicine Discipline 385
- 386 Reserve Talent Training Project (2021 No. 01).

387 9 Acknowledgments

388 The authors wish to acknowledge the authors and participants of the involved GWAS for providing 389 summary statistics data.

390 10 References

- Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet (2021) 397:1843-55. doi: 10.1016/S0140-6736(21)00569-9
- Hansildaar R, Vedder D, Baniaamam M, Tausche A-K, Gerritsen M, Nurmohamed MT.
 Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol
 (2021) 3:e58-70. doi: 10.1016/S2665-9913(20)30221-6
- 396 3. Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of 397 hyperuricemia. Am J Transl Res (2020) 12:3167-81.
- 398 4. Safiri S, Kolahi A-A, Cross M, Hill C, Smith E, Carson-Chahhoud K, et al. Prevalence, deaths,
- and disability-adjusted life years due to musculoskeletal disorders for 195 countries and territories
 1990-2017. Arthritis Rheumatol (2021) 73:702-14. doi: 10.1002/art.41571
- 401 5. Chowalloor PV, Keen HI. A systematic review of ultrasonography in gout and asymptomatic
 402 hyperuricaemia. Ann Rheum Dis (2013) 72:638-45. doi: 10.1136/annrheumdis-2012-202301
- Karantas ID, Miliotou AN, Siafaka PI. An updated review for hyperuricemia and gout
 management; special focus on the available drug delivery systems and clinical trials. Curr Med
 Chem (2023) in press. doi: 10.2174/0929867331666230809143758
- 406 7. Grzybowski A, Pietrzak K. Albert Szent-Györgyi (1893-1986): the scientist who discovered
 407 vitamin C. Clin Dermatol (2013) 31:327-31. doi: 10.1016/j.clindermatol.2012.08.001
- 408 8. Brzezińska O, Styrzyński F, Makowska J, Walczak K. Role of vitamin C in prophylaxis and

- 409 treatment of gout—A literature review. Nutrients (2021) 13:701. doi: 10.3390/nu13020701
- 410 9. Sun Y, Sun J, Wang J, Gao T, Zhang H, Ma A. Association between vitamin C intake and risk
- 411 of hyperuricemia in US adults. Asia Pac J Clin Nutr (2018) 27:1271-6. doi: 412 10.6133/apjcn.201811 27(6).0014
- 413 10. Smith GD, Hemani G. Mendelian randomization: genetic anchors for causal inference in
 414 epidemiological studies. Hum Mol Genet (2014) 23:R89-98. doi: 10.1093/hmg/ddu328
- 415 11. Lin Z, Chen H, Lan Q, Chen Y, Liao W, Guo X. Composite dietary antioxidant index is
- 416 negatively associated with hyperuricemia in US adults: An analysis of NHANES 2007-2018. Int J
- 417 Endocrinol (2023) 2023:6680229. doi: 10.1155/2023/6680229
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new
 equation to estimate glomerular filtration rate. Ann Intern Med (2009) 150:604-12. doi:
 10.7326/0003-4819-150-9-200905050-00006
- 421 13. GWAS to the people. Nat Med (2018) 24:1483. doi: 10.1038/s41591-018-0231-3
- 422 14. Hayes B. Overview of statistical methods for genome-wide association studies (GWAS).
 423 Methods Mol Biol (2013) 1019:149-69. doi: 10.1007/978-1-62703-447-0 6
- 15. Kuwabara M, Fukuuchi T, Aoki Y, Mizuta E, Ouchi M, Kurajoh M, et al. Exploring the multifaceted nexus of uric acid and health: A review of recent studies on diverse diseases.
- 426 Biomolecules (2023) 13:1519. doi: 10.3390/biom13101519.
- 427 16. Kim S-K, Choe J-Y, Park K-Y. TXNIP-mediated nuclear factor-κB signaling pathway and
- intracellular shifting of TXNIP in uric acid-induced NLRP3 inflammasome. Biochem Biophys Res
 Commun (2019) 511:725-31. doi: 10.1016/j.bbrc.2019.02.141
- 430 17. Toyoda Y, Miyata H, Uchida N, Morimoto K, Shigesawa R, Kassai H, et al. Vitamin C
 431 transporter SVCT1 serves a physiological role as a urate importer: functional analyses and in vivo
- 432 investigations. Pflugers Arch (2023) 475:489-504. doi: 10.1007/s00424-023-02792-1
- 18. So MW, Lim D-H, Kim S-H, Lee S. Dietary and nutritional factors associated with
 hyperuricemia: The seventh Korean National Health and Nutrition Examination Survey. Asia Pac J
 Clin Nutr (2020) 29:609-17. doi: 10.6133/apjcn.202009 29(3).0021
- 436 19. Lyu L-C, Hsu C-Y, Yeh C-Y, Lee M-S, Huang S-H, Chen C-L. A case-control study of the
- 437 association of diet and obesity with gout in Taiwan. Am J Clin Nutr (2003) 78:690-701. doi:
 438 10.1093/ajcn/78.4.690
- 439 20. Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral vitamin C supplementation on serum
- 440 uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) (2011)
 441 63:1295-306. doi: 10.1002/acr.20519
- 442 21. Abhishek A, Doherty M. Education and non-pharmacological approaches for gout.
 443 Rheumatology (Oxford) (2018) 57:i51-8. doi: 10.1093/rheumatology/kex421
- 444 22. Stamp LK, O'Donnell JL, Frampton C, Drake JM, Zhang M, Chapman PT. Clinically
 445 insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot
 446 randomized controlled trial. Arthritis Rheum (2013) 65:1636-42. doi: 10.1002/art.37925
- 447 23. Linster CL, Van Schaftingen E. Vitamin C. Biosynthesis, recycling and degradation in
 448 mammals. FEBS J (2007) 274:1-22. doi: 10.1111/j.1742-4658.2006.05607.x
- 449 24. Padayatty SJ, Levine M. Vitamin C: the known and the unknown and Goldilocks. Oral Dis
- 450 (2016) 22:463-93. doi: 10.1111/odi.12446
- 451 25. Li H, Liu X, Lee M-H, Li H. Vitamin C alleviates hyperuricemia nephropathy by reducing
- 452 inflammation and fibrosis. J Food Sci (2021) 86:3265-76. doi: 10.1111/1750-3841.15803

453 26. Türker PF, Hoca M, Özduran G, Ok MA, Çelebi MD. The correlation of uric acid levels with

454 biochemical parameters and dietary factors in individuals with asymptomatic hyperuricemia and

- 455 gouty arthritis. Nucleosides Nucleotides Nucleic Acids (2022) 41:444-62. doi: 456 10.1080/15257770.2022.2051047
- 457

458 **References**


- 459 [1]N Dalbeth, Gosling A-L, Gaffo A, et al. Gout[J]. Lancet, 2021, 397(10287): 1843-1855.
- 460 [2] R Hansildaar, Vedder D, Baniaamam M, et al. Cardiovascular risk in inflammatory arthritis:
 461 rheumatoid arthritis and gout[J]. Lancet Rheumatol, 2021, 3(1): e58-e70.
- 462 [3]L Li, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of 463 hyperuricemia[J]. Am J Transl Res, 2020, 12(7): 3167-3181.
- 464 [4] S Safiri, Kolahi A-A, Cross M, et al. Prevalence, Deaths, and Disability-Adjusted Life Years
- 465 Due to Musculoskeletal Disorders for 195 Countries and Territories 1990-2017[J]. Arthritis
 466 Rheumatol, 2021, 73(4): 702-714.
- [5] P-V Chowalloor, Keen H-I. A systematic review of ultrasonography in gout and asymptomatic
 hyperuricaemia[J]. Ann Rheum Dis, 2013, 72(5): 638-645.
- [6] I-D Karantas, Miliotou A-N, Siafaka P-I. An updated review for hyperuricemia and gout
 management; special focus on the available drug delivery systems and clinical trials[J]. Curr Med
 Chem, 2023.
- 472 [7] A Grzybowski, Pietrzak K. Albert Szent-Györgyi (1893-1986): the scientist who discovered
 473 vitamin C[J]. Clin Dermatol, 2013, 31(3): 327-331.
- [8] O Brzezińska, Styrzyński F, Makowska J, et al. Role of Vitamin C in Prophylaxis and Treatment
 of Gout-A Literature Review[J]. Nutrients, 2021, 13(2).
- [9] Y Sun, Sun J, Wang J, et al. Association between vitamin C intake and risk of hyperuricemia
 in US adults[J]. Asia Pac J Clin Nutr, 2018, 27(6): 1271-1276.
- 478 [10] Smith-G Davey, Hemani G. Mendelian randomization: genetic anchors for causal inference in
- 479 epidemiological studies[J]. Hum Mol Genet, 2014, 23(R1): R89-R98.
- 480 [11] Z Lin, Chen H, Lan Q, et al. Composite Dietary Antioxidant Index Is Negatively Associated
- with Hyperuricemia in US Adults: An Analysis of NHANES 2007-2018[J]. Int J Endocrinol, 2023,
 20236680229.
- 483 [12] A-S Levey, Stevens L-A, Schmid C-H, et al. A new equation to estimate glomerular filtration
- 484 rate[J]. Ann Intern Med, 2009, 150(9): 604-612.
- 485 [13] GWAS to the people[J]. Nat Med, 2018, 24(10): 1483.
- 486 [14] B Hayes. Overview of Statistical Methods for Genome-Wide Association Studies (GWAS)[J].
- 487 Methods Mol Biol, 2013, 1019149-169.
- 488 [15]M Kuwabara, Fukuuchi T, Aoki Y, et al. Exploring the Multifaceted Nexus of Uric Acid and
- 489 Health: A Review of Recent Studies on Diverse Diseases[J]. Biomolecules, 2023, 13(10).
- 490 [16]S-K Kim, Choe J-Y, Park K-Y. TXNIP-mediated nuclear factor-κB signaling pathway and
- 491 intracellular shifting of TXNIP in uric acid-induced NLRP3 inflammasome[J]. Biochem Biophys
- 492 Res Commun, 2019, 511(4): 725-731.
- 493 [17] Y Toyoda, Miyata H, Uchida N, et al. Vitamin C transporter SVCT1 serves a physiological role
- 494 as a urate importer: functional analyses and in vivo investigations[J]. Pflugers Arch, 2023, 475(4):
- 495 489-504.


- 496 [18]M-W So, Lim D-H, Kim S-H, et al. Dietary and nutritional factors associated with
- 497 hyperuricemia: The seventh Korean National Health and Nutrition Examination Survey[J]. Asia
 498 Pac J Clin Nutr, 2020, 29(3): 609-617.
- [19] L-C Lyu, Hsu C-Y, Yeh C-Y, et al. A case-control study of the association of diet and obesity
 with gout in Taiwan[J]. Am J Clin Nutr, 2003, 78(4): 690-701.
- 501 [20] S-P Juraschek, Miller ER-Rd, Gelber A-C. Effect of oral vitamin C supplementation on serum
- uric acid: a meta-analysis of randomized controlled trials[J]. Arthritis Care Res (Hoboken), 2011,
 63(9): 1295-1306.
- 504 [21] A Abhishek, Doherty M. Education and non-pharmacological approaches for gout[J].
 505 Rheumatology (Oxford), 2018, 57(suppl_1): i51-i58.
- 506 [22]L-K Stamp, O'Donnell J-L, Frampton C, et al. Clinically insignificant effect of supplemental
- vitamin C on serum urate in patients with gout: a pilot randomized controlled trial[J]. Arthritis
 Rheum, 2013, 65(6): 1636-1642.
- 509 [23]C-L Linster, Van Schaftingen E. Vitamin C. Biosynthesis, recycling and degradation in
- 510 mammals[J]. FEBS J, 2007, 274(1): 1-22.
- [24] S-J Padayatty, Levine M. Vitamin C: the known and the unknown and Goldilocks[J]. Oral Dis,
 2016, 22(6): 463-493.
- 513 [25]H Li, Liu X, Lee M-H, et al. Vitamin C alleviates hyperuricemia nephropathy by reducing
- 514 inflammation and fibrosis[J]. J Food Sci, 2021, 86(7): 3265-3276.
- 515 [26]P-F Türker, Hoca M, Özduran G, et al. The correlation of uric acid levels with biochemical
- 516 parameters and dietary factors in individuals with asymptomatic hyperuricemia and gouty
- 517 arthritis[J]. Nucleosides Nucleotides Nucleic Acids, 2022, 41(5-6): 444-462.


518 11 Data Availability Statement

519 The raw data supporting the conclusions of this article will be made available by the authors, 520 without undue reservation.

521 12 Figure Captions







Note. (A) Flow chart of NHANES 2007-2018 sample selection, (B) General design of the MR Study.





Figure 2. Restricted cubic spline analysis of the association between VC intake and HUA or Gout





13 Tables

543	Table 1. Basi	c characteristics	of participants	in the HUA study.
-----	---------------	-------------------	-----------------	-------------------

Characteristic	Ν	Overall $(N = 192, 426, 982)^1$	Non-HUA (N = $158,705,924$) ¹	HUA (N = $33,721,057$) ¹	P-value ²	
Age (year)	192,426,982	45.64 ± 16.24	45.00 ± 15.93	48.68 ± 17.26	< 0.001	
Gender, n (%)	192,426,982				< 0.001	
Male		92,355,558 (48%)	72,985,306 (46%)	19,370,251 (57%)		
Female		100,071,424 (52%)	85,720,618 (54%)	14,350,806 (43%)		
Race, n (%)	192,426,982				< 0.001	
Hispanic		30,299,598 (16%)	26,323,148 (17%)	3,976,450 (12%)		
Non-Hispanic white		124,273,125 (65%)	101,950,844 (64%)	22,322,281 (66%)		
Non-Hispanic black		22,028,503 (11%)	17,627,559 (11%)	4,400,944 (13%)		
Other race		15,825,756 (8.2%)	12,804,373 (8.1%)	3,021,383 (9.0%)		
Marital status, n (%)	192,384,707				< 0.001	
Married		108,477,283 (56%)	90,330,620 (57%)	18,146,663 (54%)		

Characteristic	N	Overall (N = $192,426,982$) ¹	Non-HUA (N = $158,705,924$) ¹	HUA $(N = 33,721,057)^1$	P-value ²
Widowed		8,788,789 (4.6%)	6,439,793 (4.1%)	2,348,996 (7.0%)	
Divorced		19,257,962 (10%)	15,335,326 (9.7%)	3,922,636 (12%)	
Unmarried		55,860,672 (29%)	46,560,485 (29%)	9,300,187 (28%)	
Education Level, n (%)	192,299,382				< 0.001
Under high school		29,191,554 (15%)	24,004,393 (15%)	5,187,160 (15%)	
High school or equivalent		44,813,137 (23%)	35,924,420 (23%)	8,888,717 (26%)	
College graduate or above		118,294,691 (62%)	98,659,627 (62%)	19,635,063 (58%)	
Poverty level	179,552,555	2.97 ± 1.66	2.98 ± 1.67	2.91 ± 1.66	0.2
Alcohol, n (%)	184,047,134	101,846,454 (55%)	83,942,947 (55%)	17,903,508 (55%)	0.8
Smoker, n (%)	192,366,786				< 0.001
Never		110,972,136 (58%)	92,650,182 (58%)	18,321,954 (54%)	
Former		44,255,187 (23%)	34,632,423 (22%)	9,622,764 (29%)	
Now		37,139,463 (19%)	31,369,386 (20%)	5,770,077 (17%)	

Characteristic	Ν	Overall $(N = 192, 426, 982)^1$	Non-HUA (N = $158,705,924$) ¹	HUA $(N = 33,721,057)^1$	P-value ²
BMI	191,205,305	29.12 ± 6.91	28.37 ± 6.51	32.71 ± 7.59	< 0.001
Waist (cm)	188,150,185	99.09 ± 16.51	97.16 ± 15.81	108.32 ± 16.66	< 0.001
Gout, n (%)	192,426,982				< 0.001
Non-gout		187,295,003 (97%)	156,242,184 (NA%)	31,052,819 (NA%)	
Gout		5,131,979 (2.7%)	2,463,740 (NA%)	2,668,239 (NA%)	
CVD, n (%)	192,426,982	13,776,816 (7.2%)	9,868,586 (6.2%)	3,908,230 (12%)	< 0.001
Hypertension, n (%)	192,426,982	55,851,108 (29%)	40,155,992 (25%)	15,695,116 (47%)	< 0.001
Hyperlipidaemia, n (%)	174,166,347	59,000,325 (34%)	46,126,903 (32%)	12,873,423 (42%)	< 0.001
Diabetes, n (%)	192,426,982	16,810,847 (8.7%)	12,361,248 (7.8%)	4,449,599 (13%)	< 0.001
Nephrolithiasis, n (%)	192,426,982	17,329,578 (9.0%)	13,753,952 (8.7%)	3,575,625 (11%)	0.006
Creatinine (µmol/L)	192,424,374	77.26 ± 29.87	74.87 ± 27.76	88.51 ± 36.22	< 0.001
Serum glucose (mmol/L)	192,426,982	5.48 ± 1.84	5.43 ± 1.84	5.72 ± 1.80	< 0.001
eGFR	192,424,374	96.24 ± 21.52	98.38 ± 20.33	86.18 ± 23.96	< 0.001

Characteristic	Ν	Overall $(N = 192, 426, 982)^1$	Non-HUA (N = $158,705,924$) ¹	HUA $(N = 33,721,057)^1$	P-value ²
Cholesterol (mmol/L)	192,426,982	5.04 ± 1.07	5.01 ± 1.06	5.17 ± 1.12	< 0.001
Triglyceride (mmol/L)	192,358,986	1.74 ± 1.44	1.65 ± 1.37	2.17 ± 1.67	< 0.001
Direct HDL cholesterol (mmol	/L)192,401,422	1.38 ± 0.42	1.40 ± 0.42	1.26 ± 0.39	< 0.001
Uric Acid (umol/L)	192,426,982	322.51 ± 83.91	296.25 ± 62.36	446.10 ± 57.95	< 0.001
Vitamin_C (mg)	192,426,982	81.47 ± 74.24	82.93 ± 74.95	74.61 ± 70.36	< 0.001
VCQ, n (%)	192,426,982				< 0.001
Q1		48,001,038 (25%)	38,120,210 (24%)	9,880,829 (29%)	
Q2		48,269,722 (25%)	40,021,703 (25%)	8,248,019 (24%)	
Q3		48,115,700 (25%)	39,684,899 (25%)	8,430,801 (25%)	
Q4		48,040,521 (25%)	40,879,112 (26%)	7,161,409 (21%)	

545 1 Mean ± SD or n (%)

⁵⁴⁶ ²Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott's second-order correction

547 Abbreviations: eGFR, glomerular filtration rate; HUA, hyperuricemia

Characteristic	Ν	Overall $(N = 192, 426, 982)^1$	Non-gout $(N = 187, 295, 003)^1$	Gout $(N = 5, 131, 979)^1$	P-value ²	
Age (year)	192,426,982	45.64 ± 16.24	45.32 ± 16.19	57.55 ± 12.94	< 0.001	
Gender, n (%)	192,426,982				< 0.001	
Male		92,355,558 (48.0%)	88,878,925 (47.5%)	3,476,633 (67.7%)		
Female		100,071,424 (52.0%)	98,416,078 (52.5%)	1,655,346 (32.3%)		
Race, n (%)	192,426,982				0.014	
Hispanic		30,299,598 (15.7%)	29,834,570 (15.9%)	465,027 (9.1%)		
Non-Hispanic white		124,273,125 (64.6%)	120,723,187 (64.5%)	3,549,938 (69.2%)		
Non-Hispanic black		22,028,503 (11.4%)	21,380,418 (11.4%)	648,085 (12.6%)		
Other race		15,825,756 (8.2%)	15,356,828 (8.2%)	468,928 (9.1%)		
Marital status	192,384,707				< 0.001	
Married		108,477,283 (56.4%)	105,141,701 (56.1%)	3,335,582 (65.0%)		
Widowed		8,788,789 (4.6%)	8,457,078 (4.5%)	331,711 (6.5%)		

Table 2. Basic characteristics of participants in the gout study. 550

Characteristic	N	Overall $(N = 192, 426, 982)^1$	Non-gout $(N = 187, 295, 003)^1$	Gout $(N = 5, 131, 979)^1$	P-value ²
Divorced		19,257,962 (10.0%)	18,523,213 (9.9%)	734,749 (14.3%)	
Unmarried		55,860,672 (29.0%)	55,133,311 (29.4%)	727,361 (14.2%)	
Education Level, n (%)	192,299,382				0.4
Under high school		29,191,554 (15.2%)	28,298,957 (15.1%)	892,597 (17.4%)	
High school or equivalent		44,813,137 (23.3%)	43,579,805 (23.3%)	1,233,333 (24.0%)	
College graduate or above		118,294,691 (61.5%)	115,288,641 (61.6%)	3,006,049 (58.6%)	
Poverty level	179,552,555	2.97 ± 1.66	2.97 ± 1.66	2.88 ± 1.68	0.4
Alcohol, n (%)	184,047,134	101,846,454 (55.3%)	99,515,325 (55.6%)	2,331,129 (46.8%)	0.006
Smoker, n (%)	192,366,786				< 0.001
Never		110,972,136 (57.7%)	108,756,367 (58.1%)	2,215,769 (43.2%)	
Former		44,255,187 (23.0%)	42,344,158 (22.6%)	1,911,029 (37.2%)	
Now		37,139,463 (19.3%)	36,134,283 (19.3%)	1,005,180 (19.6%)	
BMI	191,205,305	29.12 ± 6.91	29.03 ± 6.86	32.61 ± 7.87	< 0.001

Characteristic	Ν	Overall $(N = 192, 426, 982)^1$	Non-gout $(N = 187, 295, 003)^1$	Gout $(N = 5, 131, 979)^1$	P-value ²
Waist (cm)	188,150,185	99.09 ± 16.51	98.79 ± 16.38	110.21 ± 17.41	< 0.001
CVD, n (%)	192,426,982	13,776,816 (7.2%)	12,511,132 (6.7%)	1,265,684 (24.7%)	< 0.001
Hypertension, n (%)	192,426,982	55,851,108 (29.0%)	52,645,056 (28.1%)	3,206,052 (62.5%)	< 0.001
Hyperlipidaemia, n (%)	174,166,347	59,000,325 (33.9%)	56,265,750 (33.2%)	2,734,576 (55.4%)	< 0.001
Diabetes, n (%)	192,426,982	16,810,847 (8.7%)	15,648,533 (8.4%)	1,162,314 (22.6%)	< 0.001
Nephrolithiasis, n (%)	192,426,982	17,329,578 (9.0%)	16,557,608 (8.8%)	771,969 (15.0%)	< 0.001
HUA, n (%)	192,426,982				< 0.001
Non-HUA		158,705,924 (82.5%)	156,242,184 (NA%)	2,463,740 (NA%)	
HUA		33,721,057 (17.5%)	31,052,819 (NA%)	2,668,239 (NA%)	
Creatinine (µmol/L)	192,424,374	77.26 ± 29.87	76.69 ± 26.26	97.89 ± 88.64	< 0.001
Serum glucose (mmol/L)	192,426,982	5.48 ± 1.84	5.45 ± 1.80	6.43 ± 2.86	< 0.001
eGFR	192,424,374	96.24 ± 21.52	96.70 ± 21.32	79.37 ± 22.03	< 0.001
Cholesterol (mmol/L)	192,426,982	5.04 ± 1.07	5.03 ± 1.07	5.07 ± 1.18	0.6

Characteristic	Ν	Overall $(N = 192, 426, 982)^1$	Non-gout $(N = 187, 295, 003)^1$	Gout $(N = 5, 131, 979)^1$	P-value ²
Triglyceride (mmol/L)	192,358,986	1.74 ± 1.44	1.72 ± 1.42	2.35 ± 1.90	<0.001
Direct HDL cholesterol (mmc	ol/L)192,401,422	1.38 ± 0.42	1.38 ± 0.42	1.23 ± 0.39	< 0.001
Uric Acid (umol/L)	192,426,982	322.51 ± 83.91	320.02 ± 81.89	413.28 ± 103.94	< 0.001
Vitamin_C (mg)	192,426,982	81.47 ± 74.24	81.81 ± 74.50	69.12 ± 62.74	0.003
VCQ, n (%)	192,426,982				0.2
Q1		48,001,038 (24.9%)	46,523,048 (24.8%)	1,477,991 (28.8%)	
Q2		48,269,722 (25.1%)	46,800,328 (25.0%)	1,469,394 (28.6%)	
Q3		48,115,700 (25.0%)	46,929,892 (25.1%)	1,185,808 (23.1%)	
Q4		48,040,521 (25.0%)	47,041,735 (25.1%)	998,786 (19.5%)	

551 1 Mean ± SD or n (%)

⁵⁵² ²Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott's second-order correction

553 Abbreviations: eGFR, glomerular filtration rate; HUA, hyperuricemia

			Vitar	nin C			
Disease			Q1	Q2	Q3	Q4	P-value for trend
HUA	Model 1	OR (95% CI)		0.80 (0.70–0.91)	0.82 (0.72–0.94)	0.68 (0.59–0.78)	< 0.001
		P-value		0.001	0.005	< 0.001	
	Model 2	OR (95% CI)		0.78 (0.68–0.89)	0.81 (0.70-0.93)	0.65 (0.56-0.76)	< 0.001
		P-value		< 0.001	0.004	< 0.001	
	Model 3	OR (95% CI)		0.81 (0.68–0.96)	0.90 (0.76–1.06)	0.78 (0.65–0.93)	< 0.05
		P-value		0.014	0.2	0.007	
Gout	Model 1	OR (95% CI)		0.99 (0.64–1.52)	0.80 (0.53-1.20)	0.67 (0.46-0.97)	< 0.05
		P-value		>0.9	0.3	0.034	
	Model 2	OR (95% CI)		0.98 (0.63–1.53)	0.74 (0.47–1.16)	0.63 (0.42-0.94)	< 0.05
		P-value		>0.9	0.2	0.025	
	Model 3	OR (95% CI)		1.03 (0.65–1.63)	0.83 (0.52–1.34)	0.77 (0.50-1.20)	>0.05
		P-value		0.9	0.4	0.3	

Table 3. Association between dietary vitamin C levels (quartiles) and HUA or gout.

556 Abbreviations: HUA, hyperuricemia

Table 4. MR results for the causal effect of vitamin C on HUA and gout.

Outcome	Exposure	Method	nSNP	β	SE	OR (95% CI)	P-value
HUA	Vitamin C absorbed	MR-Egger	12	-0.026	0.011	0.974 (0.953–0.996)	0.041
		Weighted median	12	-0.020	0.009	0.980 (0.963-0.998)	0.025
		Inverse variance weighted	12	-0.015	0.006	0.985 (0.973-0.997)	0.015
		Simple mode	12	-0.017	0.016	0.983 (0.954–1.014)	0.313
		Weighted mode	12	-0.021	0.009	0.979 (0.962–0.997)	0.044
HUA	Supplements: vitamin C	MR-Egger	5	3.443	2.730	31.271 (0.148–6,589.606)	0.296
		Weighted median	5	0.045	0.402	1.046 (0.475-2.301)	0.911
		Inverse variance weighted	5	-0.219	0.629	0.803 (0.234–2.755)	0.728
		Simple mode	5	0.468	0.478	1.597 (0.626–4.077)	0.383
		Weighted mode	5	0.299	0.489	1.349 (0.518–3.514)	0.574
HUA	Medication: vitamin C	MR-Egger	4	5.387	3.805	218.551 (0.126–378,799.561)	0.293
		Weighted median	4	-1.047	1.044	0.351 (0.045-2.715)	0.316
		Inverse variance weighted	4	-1.549	1.149	0.213 (0.022–2.022)	0.178
		Simple mode	4	-0.871	1.400	0.418 (0.027-6.507)	0.578
		Weighted mode	4	-0.829	1.342	0.437 (0.031–6.053)	0.580
Gout	Vitamin C absorbed	MR-Egger	13	0.000	0.001	1.000 (0.998–1.003)	0.815
		Weighted median	13	0.001	0.001	1.001 (0.999–1.002)	0.601
		Inverse variance weighted	13	0.001	0.001	1.001 (0.999–1.002)	0.451
		Simple mode	13	0.000	0.002	1.000 (0.997–1.004)	0.822
		Weighted mode	13	0.000	0.001	1.000 (0.999–1.002)	0.686
Gout	Supplements: vitamin C	MR-Egger	6	0.012	0.177	1.012 (0.716–1.431)	0.949
		Weighted median	6	-0.101	0.046	0.904 (0.827-0.988)	0.026
		Inverse variance weighted	6	-0.155	0.037	0.857 (0.797–0.921)	0.000
		Simple mode	6	-0.095	0.065	0.909 (0.800–1.034)	0.207
		Weighted mode	6	-0.095	0.062	0.909 (0.806–1.026)	0.185
Gout	Medication: vitamin	MR-Egger	4	-0.073	0.468	0.930 (0.372–2.327)	0.891

С						
	Weighted median	4	-0.014	0.118	0.986 (0.782–1.244)	0.908
	Inverse variance weighted	4	0.020	0.102	1.020 (0.835–1.247)	0.845
	Simple mode	4	-0.090	0.171	0.914 (0.654–1.278)	0.637
	Weighted mode	4	-0.088	0.188	0.916 (0.633–1.325)	0.673

559 Abbreviations: HUA, hyperuricemia; MR, Mendelian randomisation

Outcome	F		Matha d	Cochran's Q test			MR-Egger intercept test		
	Exposure		Method	Q	Q_df	P-value	Intercept	SE	P-value
HUA	Vitamin absorbed	С	MR-Egger	19.749	11	0.049	0.002	0.002	0.153
Gout	Supplements: vitamin C Medication: vitamin C		MR-Egger	12.779	3	0.005	-0.013	0.009	0.264
			MR-Egger	2.539	2	0.281	-0.011	0.006	0.202
	Vitamin absorbed		MR-Egger	4.343	11	0.959	3.33 × 10 ⁻⁵	1.50×10^{-4}	0.829
	Supplements: vitamin C		MR-Egger	5.076	4	0.280	-5.71 × 10 ⁻⁴	5.92×10^{-4}	0.389
	Medication: vitamin C		MR-Egger	1.778	2	0.411	1.50×10^{-4}	7.38×10^{-4}	0.858

560	Table 5. Sensitivity	analysis between vitamin	n C and HUA and gout.

562 Abbreviations: HUA, hyperuricemia; MR, Mendelian randomisation

Table 6. Results for the causal effect of vitamin C on HUA and gout.

_	
E	C A
	n4

Outcome	Exposure	Method	nSNP	β	SE	OR (95% CI)	P-value
Vitamin C absorbed	C HUA	MR-Egger	102	-0.082	0.073	0.922 (0.798–1.064)	0.268
		Weighted median	102	-0.057	0.077	0.945 (0.812-1.098)	0.459
		Inverse variance weighted	102	-0.050	0.049	0.951 (0.864–1.048)	0.311
		Simple mode	102	-0.102	0.163	0.903 (0.656–1.242)	0.532
		Weighted mode	102	-0.076	0.068	0.927 (0.811-1.059)	0.269
Supplements: vitamin C	HUA	MR-Egger	338	0.000	0.002	1.000 (0.995–1.004)	0.949
		Weighted median	338	0.001	0.003	1.001 (0.996-1.006)	0.704
		Inverse variance weighted	338	-0.004	0.002	0.996 (0.992-0.999)	0.013
		Simple mode	338	-0.004	0.009	0.996 (0.979–1.012)	0.604
		Weighted mode	338	0.000	0.002	1.000 (0.995-1.005)	0.981
Medication: vitamin C	HUA	MR-Egger	261	0.003	0.002	1.003 (1.000–1.006)	0.044
		Weighted median	261	0.003	0.001	1.003 (1.001–1.006)	0.016
		Inverse variance weighted	261	0.000	0.001	1.000 (0.998–1.002)	0.848
		Simple mode	261	-0.009	0.004	0.991 (0.983-0.999)	0.033
		Weighted mode	261	0.002	0.001	1.002 (1.000-1.005)	0.071
Vitamin C absorbed	C Gout	MR-Egger	5	-1.844	1.723	0.158 (0.005–4.638)	0.363
		Weighted median	5	-1.545	1.222	0.213 (0.019-2.340)	0.206
		Inverse variance weighted	5	-1.378	1.195	0.252 (0.024–2.626)	0.249
		Simple mode	5	-0.999	2.919	0.368 (0.001–112.413)	0.749
		Weighted mode	5	-1.577	1.247	0.207 (0.018–2.378)	0.275
Supplements: vitamin C	Gout	MR-Egger	12	-0.624	0.560	0.536 (0.179–1.606)	0.291
		Weighted median	12	-0.195	0.177	0.823 (0.582-1.163)	0.269
		Inverse variance weighted	12	-0.195	0.170	0.823 (0.589–1.149)	0.252
		Simple mode	12	-0.157	0.236	0.854 (0.538–1.358)	0.519

		Weighted mode	12	-0.137	0.226	0.872 (0.560-1.358)	0.556
Medication:	Gout	MR-Egger	10	-0.497	0.430	0.609 (0.262–1.415)	0.282
vitamin C		XX7 · 1 / 1 1 ·	10	0.022	0.077	0.0(0.00, 0.000, 1.105)	0.00
		Weighted median	10	-0.033	0.077	0.968 (0.833–1.125)	0.668
		Inverse variance weighted	10	0.019	0.076	1.020 (0.878–1.183)	0.799
		Simple mode	10	-0.122	0.132	0.885 (0.683-1.147)	0.380
		Weighted mode	10	-0.122	0.141	0.885 (0.671–1.167)	0.409

565 Abbreviations: HUA, hyperuricemia; MR, Mendelian randomisation

Outeenee		Exposure	M	Cochran's Q test			MR-Egger inte	MR-Egger intercept test		
Outcome			Method	Q	Q_df	P-value	Intercept	SE	P-value	
Vitamin absorbed	С	HUA	MR-Egger	15.422	100	1.000	1.13 × 10 ⁻³	0.002	0.560	
Supplements: vitamin C			MR-Egger	392.890	336	0.018	-1.62×10^{-4}	6.15×10^{-5}	0.009	
Medication: vitamin C			MR-Egger	298.481	259	0.046	-7.30×10^{-5}	3.12×10^{-5}	0.020	
Vitamin absorbed	С	Gout	MR-Egger	0.386	3	0.943	0.004	0.011	0.732	
Supplements: vitamin C			MR-Egger	19.467	10	0.035	7.59×10^{-4}	9.43 × 10 ⁻⁴	0.440	
Medication: vitamin C			MR-Egger	15.426	8	0.051	8.18×10^{-4}	6.72×10^{-4}	0.258	

Table 7. Sensitivity analysis between vitamin C and HUA and gout.

569 Abbreviations: HUA, hyperuricemia; MR, Mendelian randomisation